Attached files
file | filename |
---|---|
EX-99.17 (AS APPROP) - PRESS RELEASE - OWC Pharmaceutical Research Corp. | exh99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM 8-K
___________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): January 27, 2017
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of
Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware | 98-0573566 |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
30 Shacham Street, P.O.B. 8324, Petach Tikva, Israel | 4918103 |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant's Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events. On January 27, 2017, OWC Pharmaceutical
Research Corp. issued a press release announcing that Ms. Miri Sani has accepted
her nomination to the Company's Advisory Board. The press release is attached to
this Form 8-K as Exhibit 99.1. Exhibit
No. Date: January 27, 2017
Description
99.1
Press Release issued by OWC
Pharmaceutical Research Corp. dated January 27, 2017.
OWC Pharmaceutical
Research Corp.
By:
/s/ Mordechai
Bignitz
Name:
Mordechai Bignitz
Title:
Chief Executive
Officer